NCT05319873
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Endocrine (Hormone) Therapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Metastatic breast cancer patients are only eligible for phase 1 of the study; Patients must have received 1 or more prior lines of HER2 directed therapy in the metastatic setting; Patients are NOT required to have brain metastasis to participate
Exclusions: Patients with known or suspected leptomeningeal disease (LMD)
https://ClinicalTrials.gov/show/NCT05319873